Clinical Trial

A Study of HS-20106 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated September 19, 2024 (before its estimated October 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of HS-20106 on anemia in patients with very low, low or intermediate risk MDS.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-09-10.
Status change: Recruiting → Not Yet Recruiting 2024-09-14
Trial Details
NCT Number NCT06594965
Lead Sponsor Hansoh BioMedical R&D Company
Conditions Myelodysplastic Syndromes, Anemia, MDS, Bone Marrow Disease
Enrollment 176 participants
Start Date 2024-10-30
Primary Completion 2025-10-30 (estimated)
Study Completion 2026-10-30 (estimated)
Updated on ClinicalTrials.gov 2024-09-19